Psomagen, Inc. (KOSDAQ:950200)

Market Cap	71.56B
Revenue (ttm)	52.65B
Net Income (ttm)	-5.19B
Shares Out	19.24M
EPS (ttm)	-262.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,463
Average Volume	15,114
Open	3,775.00
Previous Close	3,755.00
Day's Range	3,720.00 - 3,775.00
52-Week Range	2,910.00 - 5,090.00
Beta	0.09
RSI	40.59
Earnings Date	Nov 14, 2025

About Psomagen

Psomagen, Inc. engages in the provision omics solutions and contract laboratory services. The company’s research services comprises of genomics, a study of gene sequence and expression; epigenomics, a study of epigenetic changes, such as chromatin assembly, histone modification, and DNA-protein interaction in a cell; single-cell analysis, research in suspensions, biological fluids, tissues, or cell populations; metagenomics, a study of genetic material from microorganisms in heterogeneous samples; transcriptomics, a study of RNA and its express...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 89
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950200

Financial Performance

In 2024, Psomagen's revenue was 43.66 billion, an increase of 35.29% compared to the previous year's 32.27 billion. Losses were -5.62 billion, 31.0% more than in 2023.